Aerovate Therapeutics (NASDAQ:AVTE) Stock Jumps 0.1% – Still a Buy?

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) shot up 0.1% during trading on Thursday. The stock traded as high as $13.6550 and last traded at $13.44. 1,172,683 shares were traded during mid-day trading, an increase of 2,088% from the average session volume of 53,591 shares. The stock had previously closed at $13.42.

Aerovate Therapeutics Price Performance

The business has a fifty day moving average of $18.28 and a 200 day moving average of $19.71. The stock has a market cap of $390.43 million, a price-to-earnings ratio of -4.51 and a beta of 0.95.

Aerovate Therapeutics Company Profile

Aerovate Therapeutics, Inc was a clinical-stage biopharmaceutical company focused on developing therapies for pulmonary arterial hypertension (PAH) and other serious pulmonary vascular diseases. The company’s lead product candidate was AV-101, an inhaled dry-powder formulation of imatinib intended to target the underlying vascular remodeling associated with PAH.

AV-101 was evaluated in clinical studies, including the IMPAHCT program, for patients with pulmonary arterial hypertension. The company did not have an approved commercial product and operated primarily as a research and development organization serving the biopharmaceutical market.

In 2024, Aerovate reported that the IMPAHCT study did not meet its primary efficacy endpoint and announced plans to discontinue development of AV-101, reduce its workforce and wind down operations while evaluating strategic alternatives.